VBI Vaccines Inc.
VBIV · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.01 | -0.26 | 0.24 |
| FCF Yield | -674.95% | -77.48% | -7.02% | -8.01% |
| EV / EBITDA | -0.47 | -0.85 | -8.07 | -12.30 |
| Quality | ||||
| ROIC | -86.51% | -68.13% | -37.93% | -22.49% |
| Gross Margin | -66.98% | -942.14% | -1,606.81% | -764.09% |
| Cash Conversion Ratio | 0.66 | 0.65 | 0.57 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 139.62% | 0.66% | -34.26% | -31.87% |
| Free Cash Flow Growth | 20.87% | -86.24% | 12.79% | 8.28% |
| Safety | ||||
| Net Debt / EBITDA | -0.35 | 0.10 | 1.43 | 2.25 |
| Interest Coverage | -6.86 | -15.67 | -13.33 | -13.13 |
| Efficiency | ||||
| Inventory Turnover | 1.71 | 0.00 | 4.18 | 4.26 |
| Cash Conversion Cycle | 105.38 | 972.26 | 778.68 | 2,657.14 |